ClinicalTrials.gg

Program

GSK4024484C

A development code.

In GlaxoSmithKline's pipeline, P. falciparum whole cell inhibitor. Its studies are mostly in Malaria, Falciparum, led by GlaxoSmithKline.

Furthest: phase 1, since Dec 6, 20231 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 1since Dec 6, 2023Dec 6, 2023none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK4024484, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 6, 2023First study: phase 1 study in Malaria, FalciparumFirst studyNCT06171113 · 123 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“P. falciparum whole cell inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06171113Malaria, Falciparum · United Kingdom1CompletedJun 16, 2026123

How it is read

Names in the registry

  • “GSK4024484C”, 1 entry

Codes read as this program: GSK4024484C.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.